How comparing works here
How do I compare two companies?
Type the tickers into the box above — up to five at once. Every row is read from the companies' own annual filings, so a comparison shows the same measure computed the same way for each of them rather than whatever each company chose to highlight.
Can I compare an ETF with a stock?
Yes, and the table changes to suit. Two funds are compared on cost, income, spread and record, because revenue growth and debt mean nothing for a fund. A fund against a company shows only what both of them have.
Side by side
Compare
Put up to 4 companies, funds, commodities or coins next to each other — health, valuation, growth and performance.
Every row is computed the same way for every column, from each company's own annual filing, so a comparison is not a collection of whichever figures each of them chose to put in a press release. Funds are compared on what a fund is actually judged on: cost, income, spread and record.
Relative performance
Rebased so every symbol starts at 0%
Loading price history…
Side by side
Latest annual figures from each company's filings
| Metric | RVMDRevolution Medicines, Inc. | VRTXVERTEX PHARMACEUTICALS INC / MA | MRNAModerna, Inc. | REGNREGENERON PHARMACEUTICALS, INC. | Median of the restexcluding RVMD |
|---|---|---|---|---|---|
| Type | Company | Company | Company | Company | |
| Price | $194.28▼ 2.27 (1.15%) | $524.52▲ 9.87 (1.92%) | $245.81▲ 3.73 (1.54%) | $805.67▼ 1.81 (0.22%) | |
| Health scoreComposite of profitability, growth, debt and accounting quality. | 2.0/10 | 8.7/10 | 6.0/10 | 8.7/10 | 8.7/10 |
| Market value | $38.27B | $133.22B | $96.85B | $84.27B | |
| Revenue | $0.00 | $12.00B | $1.94B | $14.34B | |
| Profit | -$1.13B | $3.95B | -$2.82B | $4.50B | |
| Revenue growthChange in sales versus the prior year. | — | 8.9% | -39.9% | 1.0% | 1.0% |
| Gross marginShare of sales left after the direct cost of producing them. | — | 86.2% | 55.3% | — | 70.8% |
| Operating marginShare of sales left after running the business, before interest and tax. | — | 34.8% | -158.1% | 24.9% | 24.9% |
| Profit marginProfit kept from each dollar of sales. | — | 32.9% | -145.2% | 31.4% | 31.4% |
| Free cash flow marginCash left after capital spending, as a share of sales. | — | 26.6% | -106.2% | 28.4% | 26.6% |
| Return on equityProfit against the owners' stake in the company. | -69.3% | 21.2% | -32.6% | 14.4% | 14.4% |
| Return on invested capital (approx.)Operating profit after tax against equity plus debt, less cash. Cash here excludes short-term investments, so this runs low for cash-rich companies. | -74.9% | 26.2% | -36.5% | 10.2% | 10.2% |
| P/E ratioPrice paid per dollar of annual profit. | — | 33.70x | — | 18.71x | 26.20x |
| EV / EBITDA (approx.)Market value plus debt less cash, against operating profit before depreciation. Cash excludes short-term investments, so this runs high for cash-rich companies. | — | — | — | 20.17x | 20.17x |
| Price to book | 23.46x | 7.14x | 11.20x | 2.70x | 7.14x |
| Debt to equityTotal liabilities compared with owners' stake. | 0.44x | 0.37x | 0.43x | 0.30x | 0.37x |
| Piotroski F-ScoreNine checks of financial strength. Higher is stronger. | 1/7 | 6/8 | 3/9 | 6/8 | 6.0 |
| Bankruptcy riskAltman Z-Score zone. | safe | safe | safe | safe |
How RVMD compares with the others
- Its liabilities are higher relative to equity than the median of the other companies selected: 0.4x against 0.4x.
Measured against the other companies entered, from each one's latest annual filing. A difference describes the companies; it does not rank them.